Exosomes as adjuvants for the recombinant hepatitis B antigen: First report

Jesus, Sandra; Soares, Edna; Cruz, Maria Teresa

doi:10.1016/j.ejpb.2018.09.029

Cited by 52 publications

(43 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, EVs also triggered an immunomodulator effect on the cellular immune response, highlighted by the enhance of IFNγ secretion. Interestingly, Jesus et al, detected a shift toward a Th1 response, which was observed before when using EVs as an adjuvant in vivo (Aline et al, 2004;Qazi et al, 2009;Jesus et al, 2018). One issue that was not addressed is whether potential LPS contamination of their isolated exosomes could be partly responsible for the immune responses.…”

Section: Role Of Evs In the Development Of Viral Vaccinesmentioning

confidence: 96%

“…A Th1-type shift cannot be achieved with alum or lipopolysaccharides (LPS), other commonly used adjuvants, which underlines the potential of EVs as adjuvants (Awate et al, 2013). Similarly, another group (Jesus et al, 2018) described the role of unmodified exosomes as adjuvants for hepatitis B vaccination strategies. They isolated EVs from the supernatant of LPS-stimulated human monocytic cell lines (THP-1) and showed that they evoked a pro-inflammatory profile in spleen cells of healthy mice through the induction of cytokines.…”

Section: Role Of Evs In the Development Of Viral Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

Dogrammatzis

Waisner

Kalamvoki

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Extracellular vesicles (EVs) constitute a heterogeneous group of vesicles released by all types of cells that play a major role in intercellular communication. The field of EVs started gaining attention since it was realized that these vesicles are not waste bags, but they carry specific cargo and they communicate specific messages to recipient cells. EVs can deliver different types of RNAs, proteins, and lipids from donor to recipient cells and they can influence recipient cell functions, despite their limited capacity for cargo. EVs have been compared to viruses because of their size, cell entry pathways, and biogenesis and to viral vectors because they can be loaded with desired cargo, modified, and re-targeted. These properties along with the fact that EVs are stable in body fluids, they can be produced and purified in large quantities, they can cross the blood-brain barrier, and autologous EVs do not appear to cause major adverse effects, have rendered them attractive for therapeutic use. Here, we discuss the potential for therapeutic use of EVs derived from virus infected cells or EVs carrying viral factors. We have focused on six major concepts: (i) the role of EVs in virus-based oncolytic therapy or virus-based gene delivery approaches; (ii) the potential use of EVs for developing viral vaccines or optimizing already existing vaccines; (iii) the role of EVs in delivering RNAs and proteins in the context of viral infections and modulating the microenvironment of infection; (iv) how to take advantage of viral features to design effective means of EV targeting, uptake, and cargo packaging; (v) the potential of EVs in antiviral drug delivery; and (vi) identification of novel antiviral targets based on EV biogenesis factors hijacked by viruses for assembly and egress. It has been less than a decade since more attention was given to EV research and some interesting concepts have already been developed. In the coming years, additional information on EV biogenesis, how they are hijacked and utilized by pathogens, and their impact on the microenvironment of infection is expected to indicate avenues to optimize existing therapeutic tools and develop novel approaches.

show abstract

Section: Role Of Evs In the Development Of Viral Vaccinesmentioning

confidence: 96%

Section: Role Of Evs In the Development Of Viral Vaccinesmentioning

confidence: 99%

Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

Dogrammatzis

Waisner

Kalamvoki

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…They also play many roles in HBV infection; they are responsible for HBV replication, innate immune response during infection, a biomarker for its diagnosis, and development of a possible vaccine [198,199]. A recent study elucidated that unmodified EVs can be attractive coadjutants to hepatitis B recombinant antigen (HBsAg), because it triggers the healthy mice immune response due to an increased IFN-γ concentration and accelerates the production of IgG antibodies [200]. HepG2.2.15 cells with integrated HBV genome release EVs containing HBV-miR-3 which represses viral protein production and HBV replication [143].…”

Section: Other Viral Infections and Evsmentioning

confidence: 99%

Extracellular Vesicles in Viral Replication and Pathogenesis and Their Potential Role in Therapeutic Intervention

Kumar

Tadrous

et al. 2020

Viruses

View full text Add to dashboard Cite

Extracellular vesicles (EVs) have shown their potential as a carrier of molecular information, and they have been involved in physiological functions and diseases caused by viral infections. Virus-infected cells secrete various lipid-bound vesicles, including endosome pathway-derived exosomes and microvesicles/microparticles that are released from the plasma membrane. They are released via a direct outward budding and fission of plasma membrane blebs into the extracellular space to either facilitate virus propagation or regulate the immune responses. Moreover, EVs generated by virus-infected cells can incorporate virulence factors including viral protein and viral genetic material, and thus can resemble noninfectious viruses. Interactions of EVs with recipient cells have been shown to activate signaling pathways that may contribute to a sustained cellular response towards viral infections. EVs, by utilizing a complex set of cargos, can play a regulatory role in viral infection, both by facilitating and suppressing the infection. EV-based antiviral and antiretroviral drug delivery approaches provide an opportunity for targeted drug delivery. In this review, we summarize the literature on EVs, their associated involvement in transmission in viral infections, and potential therapeutic implications.

show abstract

“…The understanding of immunomodulation mechanism through EV during viral liver infection could help the development of therapies towards infection or preventive strategies. For instance, Jesus et al using a mouse model reported that EV obtained from stimulated monocytes (THP‐1) were an efficient adjuvant for HBV HBs antigen vaccination by triggering a specific cellular response with enhanced interferon‐γ (INF‐γ) production measured in isolated spleen cells …”

Section: Extracellular Vesicles In Chronic Liver Diseasesmentioning

confidence: 99%

Extracellular vesicles: Future diagnostic and therapeutic tools for liver disease and regeneration

Balaphas

Meyer

Sadoul

et al. 2019

Liver International

View full text Add to dashboard Cite

Extracellular vesicles are membrane fragments that can be produced by all cell types. Interactions between extracellular vesicles and various liver cells constitute an emerging field in hepatology and recent evidences have established a role for extracellular vesicles in various liver diseases and physiological processes. Extracellular vesicles originating from liver cells are implicated in intercellular communication and fluctuations of specific circulating extracellular vesicles could constitute new diagnostic tools. In contrast, extracellular vesicles derived from progenitor cells interact with hepatocytes or non‐parenchymal cells, thereby protecting the liver from various injuries and promoting liver regeneration. Our review focuses on recent developments investigating the role of various types of extracellular vesicles in acute and chronic liver diseases as well as their potential use as biomarkers and therapeutic tools.

show abstract

Exosomes as adjuvants for the recombinant hepatitis B antigen: First report

Cited by 52 publications

References 38 publications

Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

Extracellular Vesicles in Viral Replication and Pathogenesis and Their Potential Role in Therapeutic Intervention

Extracellular vesicles: Future diagnostic and therapeutic tools for liver disease and regeneration

Contact Info

Product

Resources

About